These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 7314875)

  • 41. Dialysis therapy: 'think differently'.
    Perrone B
    Nephrol Dial Transplant; 2007 Jul; 22 Suppl 5():v1-2. PubMed ID: 17586840
    [No Abstract]   [Full Text] [Related]  

  • 42. Middle molecules in renal failure.
    Leber HW; Goubeaud G; Spiegelhalter R
    Ann Clin Biochem; 1979 Nov; 16(6):389-95. PubMed ID: 539797
    [No Abstract]   [Full Text] [Related]  

  • 43. Uremic toxins and vitamin D metabolism.
    Hsu CH; Patel SR
    Kidney Int Suppl; 1997 Nov; 62():S65-8. PubMed ID: 9350684
    [No Abstract]   [Full Text] [Related]  

  • 44. Uremic neurotoxin in the middle molecular weight range.
    Man NK; Cueille G; Zingraff J; Boudet J; Sausse A; Funck-Brentano JL
    Artif Organs; 1980 May; 4(2):116-20. PubMed ID: 7396764
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Erythrocyte transport of middle molecular substances.
    Gajdos M; Spustová V; Geryková M; Dzúrik R
    Proc Eur Dial Transplant Assoc; 1981; 18():183-7. PubMed ID: 7329966
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [The use of liquid exclusion chromatography for evaluating methods of treating urologic diseases].
    Kon'kova TA; D'iakov VL; Danilkov AP; Chudnovskaia MV
    Lab Delo; 1990; (12):19-23. PubMed ID: 1710686
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Identification of two uremic toxins by nuclear magnetic resonance and mass spectrometry.
    Monti JP; Gallice P; Braguer D; Durand C; Murisasco A; Crevat A
    Adv Exp Med Biol; 1987; 223():223-6. PubMed ID: 3447439
    [No Abstract]   [Full Text] [Related]  

  • 48. Membrane and chromatography separation techniques for the preparative isolation of uremic toxins.
    Brunner H; Mann H
    Life Support Syst; 1983; 1 Suppl 1():199-206. PubMed ID: 6336410
    [No Abstract]   [Full Text] [Related]  

  • 49. Amino acid composition of uremic middle and low molecular weight retention products.
    Bazilinski N; Shaykh M; Ahmed S; Musiala T; Williams RH; Poulos A; Dubin A; Dunea G
    Adv Exp Med Biol; 1987; 223():197-204. PubMed ID: 3447436
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Middle molecule levels in patients with spinal cord trauma].
    Petrova NV; Eroshkina TD
    Vopr Med Khim; 1994; 40(5):53-5. PubMed ID: 7839674
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mathematical formulation of the dialysis index for middle molecules, D1(MM).
    Milutinovic J; Babb AL; Eschbach JW; Follette WC; Graefe U; Strand MJ; Scribner BH
    Artif Organs; 1978 Feb; 2(1):51-4. PubMed ID: 687021
    [No Abstract]   [Full Text] [Related]  

  • 52. Studies on uremic toxins; structure-activity correlation in H-Asp(Gly)-OH.
    Abiko T; Kumikawa M; Dazai S; Takahashi H; Ishizaki M; Sekino H
    Biochem Biophys Res Commun; 1978 May; 82(2):707-15. PubMed ID: 666867
    [No Abstract]   [Full Text] [Related]  

  • 53. Separation, identification of uremic middle molecules, and preliminary study on their toxicity.
    Li G; Chu J; Liu X; Yuan Z
    Clin Chim Acta; 2004 Dec; 350(1-2):89-98. PubMed ID: 15530464
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Effect of "uremia toxins" on exocrine secretion of the isolated pancreas].
    Wizemann V; Klewer H; Wiesenecker C; Schütterle G
    Verh Dtsch Ges Inn Med; 1974; 80():718-20. PubMed ID: 4454644
    [No Abstract]   [Full Text] [Related]  

  • 55. Combination of conventional and high-performance liquid chromatographic techniques for the isolation of so-called "uraemic toxins".
    Brunner H; Mann H
    J Chromatogr; 1984 Aug; 297():405-16. PubMed ID: 6490772
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Retention patterns.
    Schoots A; Vanholder R; Ringoir S; Cramers C
    Adv Exp Med Biol; 1987; 223():19-26. PubMed ID: 3447434
    [No Abstract]   [Full Text] [Related]  

  • 57. [Fluorescent component found in uremic middle-molecules in the hemofiltrate of a dialysis patient].
    Konobu K; Matsumoto T; Sawanishi K
    Nihon Jinzo Gakkai Shi; 1988 Feb; 30(2):161-7. PubMed ID: 3386020
    [No Abstract]   [Full Text] [Related]  

  • 58. [Middle-molecular uremic toxins (review of the literature)].
    Tupikova ZA
    Vopr Med Khim; 1983; 29(1):2-10. PubMed ID: 6340339
    [No Abstract]   [Full Text] [Related]  

  • 59. Middle molecules and the 7 C factor.
    Bergström J; Jörnvall H; Zimmerman L
    Adv Exp Med Biol; 1987; 223():27-32. PubMed ID: 3447445
    [No Abstract]   [Full Text] [Related]  

  • 60. Review on uraemic toxins III: recommendations for handling uraemic retention solutes in vitro--towards a standardized approach for research on uraemia.
    Cohen G; Glorieux G; Thornalley P; Schepers E; Meert N; Jankowski J; Jankowski V; Argiles A; Anderstam B; Brunet P; Cerini C; Dou L; Deppisch R; Marescau B; Massy Z; Perna A; Raupachova J; Rodriguez M; Stegmayr B; Vanholder R; Hörl WH;
    Nephrol Dial Transplant; 2007 Dec; 22(12):3381-90. PubMed ID: 17724037
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.